MedTrace Logo

Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium

NCT04221802 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2025-05-06

No results posted yet for this study

Summary

This study aims to assess health and quality of life outcomes in patients treated with benralizumab, within a Belgian Real-World setting. To prove the clinical value of benralizumab in a Real-World setting, the study will document the effect of benralizumab within a time frame of 112 weeks after initiation of treatment.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Dupont Lieve, Prof. · Universitair Zienkenhuis Leuven

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-23
Primary Completion
2024-05-13
Completion
2024-05-13

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04221802 on ClinicalTrials.gov